drugset / Trial / NCT02414880

Sugammadex Versus Neostigmine in Patients With Liver Cirrhosis Undergoing Liver Resection

NCT02414880

RandomizedParallel-groupOpen-labelTreatment

Summary

Liver cirrhosis is a progressive disease characterized by loss of functional hepatocytes that substantially affects drug pharmacokinetics. Rocuronium onset time is longer and recovery time from it is prolonged in cirrhotic patients than in those with normal liver function. This randomized controlled study is designed to compare the pharmacodynamic profiles of sugammadex and neostigmine when used for the antagonism of moderate degree of rocuronium-induced neuromuscular block in cirrhotic patients undergoing liver resection and in patients with preoperative normal liver functions undergoing liver resection.

Timeline

Start
2014-12
Primary completion
2015-08
Completion
2015-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Neostigmine Other / unclassified 50 ug/kg Other
Comparator Sugammadex Other / unclassified 2 mg/kg Other
Comparator Rocuronium Other / unclassified 0.15 mg/kg

Indications